XML 87 R76.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 16,112 | $ 15,035 | $ 31,887 | $ 29,522
Increase in hedge revenue |  |  | 118 | 128
Revenue related to the sale of the marketing rights |  |  | 76 | 54
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,876 | 7,018 | 15,354 | 13,676
Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,236 | 8,018 | 16,533 | 15,846
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15,890 | 14,913 | 31,408 | 29,126
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,854 | 7,045 | 15,265 | 13,644
Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,036 | 7,869 | 16,143 | 15,482
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 222 | 122 | 479 | 396
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | (27) | 89 | 32
Corporate, Non-Segment | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 200 | 149 | 390 | 364
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,408 | 13,457 | 28,415 | 26,179
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,399 | 6,570 | 14,336 | 12,688
Pharmaceutical | Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,009 | 6,887 | 14,079 | 13,491
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,270 | 6,271 | 14,217 | 12,065
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,412 | 3,863 | 8,531 | 7,348
Pharmaceutical | Operating Segments | Keytruda | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,858 | 2,408 | 5,686 | 4,718
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 317 | 310 | 609 | 585
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 144 | 288 | 286
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 165 | 166 | 321 | 299
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 249 | 242 | 504 | 474
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 177 | 163 | 349 | 316
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 79 | 155 | 158
Pharmaceutical | Operating Segments | Welireg |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 126 | 50 | 211 | 92
Pharmaceutical | Operating Segments | Welireg | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 116 | 49 | 194 | 90
Pharmaceutical | Operating Segments | Welireg | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10 | 2 | 17 | 3
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 90 | 47 | 161 | 90
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 36 | 133 | 66
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 11 | 28 | 24
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,478 | 2,458 | 4,727 | 4,430
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 536 | 464 | 1,024 | 880
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,941 | 1,994 | 3,702 | 3,550
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 617 | 582 | 1,187 | 1,109
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 490 | 447 | 928 | 868
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 127 | 135 | 259 | 242
Pharmaceutical | Operating Segments | Vaxneuvance |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 189 | 168 | 408 | 274
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 99 | 147 | 260 | 241
Pharmaceutical | Operating Segments | Vaxneuvance | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 90 | 20 | 148 | 33
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 163 | 131 | 379 | 428
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 107 | 93 | 257 | 273
Pharmaceutical | Operating Segments | RotaTeq | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 37 | 123 | 155
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 59 | 92 | 120 | 188
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11 | 23 | 17 | 63
Pharmaceutical | Operating Segments | Pneumovax 23 | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 69 | 103 | 125
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 455 | 502 | 895 | 989
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 351 | 299 | 680 | 576
Pharmaceutical | Operating Segments | Bridion | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 104 | 203 | 215 | 413
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 188 | 143 | 362 | 273
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 90 | 61 | 165 | 116
Pharmaceutical | Operating Segments | Prevymis | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 82 | 197 | 157
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 76 | 165 | 141
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 79 | 68 | 147 | 130
Pharmaceutical | Operating Segments | Dificid | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12 | 8 | 17 | 11
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 62 | 54 | 118 | 104
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 33 | 30 | 67 | 57
Pharmaceutical | Operating Segments | Zerbaxa | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 28 | 24 | 51 | 47
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 55 | 101 | 116
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 11 | 8 | 25
Pharmaceutical | Operating Segments | Noxafil | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 45 | 92 | 91
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 106 | 68 | 203 | 167
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 70 | 188 | 153
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8 | (2) | 16 | 14
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 65 | 142 | 125
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 65 | 142 | 125
Pharmaceutical | Operating Segments | Winrevair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 0 | 70 | 0
Pharmaceutical | Operating Segments | Winrevair | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 0 | 70 | 0
Pharmaceutical | Operating Segments | Winrevair | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 110 | 203 | 460 | 595
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 2 | 60 | 0
Pharmaceutical | Operating Segments | Lagevrio | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 95 | 201 | 400 | 595
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 89 | 136 | 200 | 259
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 56 | 93 | 108
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | 80 | 107 | 151
Pharmaceutical | Operating Segments | Delstrigo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 50 | 116 | 94
Pharmaceutical | Operating Segments | Delstrigo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14 | 13 | 26 | 24
Pharmaceutical | Operating Segments | Delstrigo | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 37 | 89 | 70
Pharmaceutical | Operating Segments | Pifeltro |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 38 | 81 | 72
Pharmaceutical | Operating Segments | Pifeltro | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 27 | 27 | 56 | 51
Pharmaceutical | Operating Segments | Pifeltro | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12 | 11 | 25 | 21
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 63 | 99 | 119
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 19 | 21 | 33 | 37
Pharmaceutical | Operating Segments | Belsomra | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 34 | 42 | 66 | 82
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 172 | 180 | 356 | 359
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 172 | 180 | 356 | 359
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 48 | 74 | 99
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 48 | 74 | 99
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 405 | 511 | 824 | 1,062
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 177 | 243 | 361 | 514
Pharmaceutical | Operating Segments | Januvia | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 227 | 267 | 463 | 548
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 224 | 354 | 475 | 683
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 17 | 82 | 55 | 138
Pharmaceutical | Operating Segments | Janumet | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 208 | 272 | 420 | 544
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 573 | 560 | 1,151 | 1,187
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 158 | 346 | 328
Pharmaceutical | Operating Segments | Other pharmaceutical | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 386 | 403 | 807 | 857
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,482 | 1,456 | 2,993 | 2,947
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 455 | 475 | 929 | 956
Animal Health | Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,027 | 982 | 2,064 | 1,991
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 837 | 807 | 1,686 | 1,656
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 168 | 165 | 334 | 338
Animal Health | Operating Segments | Livestock | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 669 | 643 | 1,352 | 1,318
Animal Health | Operating Segments | Companion Animal |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 645 | 649 | 1,307 | 1,291
Animal Health | Operating Segments | Companion Animal | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 287 | 310 | 595 | 618
Animal Health | Operating Segments | Companion Animal | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 358 | $ 339 | $ 712 | $ 673

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WinrevairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DelstrigoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PifeltroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |